SHH and skin basal cell carcinoma: Although much has been achieved through the targeting of key molecules for therapy, such as Shh inhibitors used to treat against BCC, there are still many challenges, such as determining the mechanistic framework in HFSCs, overcoming the limited efficacy of targeted drugs, shortening the length of treatments, and minimizing possible adverse side effects.